As per the terms of the agreement, Probiomed is responsible for seeking regulatory approval for Fanapt in Mexico.
However, Vanda will be responsible for supplying the drug to Probiomed for promoting and selling the drug.
Probiomed founder and CEO Jaime Uribe de la Mora said theye expect to submit the regulatory dossier for market authorization review by the end of 2011.